Coexpressed catalase protects chimeric antigen receptor-redirected T cells as well as bystander cells from oxidative stress-induced loss of antitumor activity

Journal of Immunology

Volumn 196, Issue 2, 2016, Pages 759-766

  Ligtenberg, Maarten A ^a   Mougiakakos, Dimitrios ^b   Mukhopadhyay, Madhura ^a   Witt, Kristina ^a   Lladser, Alvaro ^c   Chmielewski, Markus ^d   Riet, Tobias ^d   Abken, Hinrich ^d   Kiessling, Rolf ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c Fundacion Ciencia para la Vida   (Chile)

^d UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CATALASE; CHIMERIC ANTIGEN RECEPTOR; HYDROGEN PEROXIDE; REACTIVE OXYGEN METABOLITE; CAT PROTEIN, HUMAN; HYBRID PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR;

ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ANTIOXIDANT ASSAY; ARTICLE; BIOACCUMULATION; CONTROLLED STUDY; EFFECTOR CELL; HUMAN; HUMAN CELL; LYMPHOCYTE ACTIVATION; LYMPHOCYTE FUNCTION; NATURAL KILLER CELL; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN TRANSPORT; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; ADOPTIVE IMMUNOTHERAPY; BYSTANDER EFFECT; CELL LINE; CELL SEPARATION; GENETIC TRANSFECTION; IMMUNOLOGY; PHYSIOLOGY; PROCEDURES; WESTERN BLOTTING;

BLOTTING, WESTERN; BYSTANDER EFFECT; CATALASE; CELL LINE; CELL SEPARATION; HUMANS; IMMUNOTHERAPY, ADOPTIVE; KILLER CELLS, NATURAL; OXIDATIVE STRESS; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES; TRANSFECTION;

EID: 84954164946     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1401710     Document Type: Article

References (46)

1. Fridman, W.-H., F. Pagès, C. Sautès-Fridman, and J. Galon. 2012. The immune contexture in human tumours: impact on clinical outcome. Nat. Rev. Cancer 12: 298-306.
2. Büning, H., W. Uckert, K. Cichutek, R. E. Hawkins, and H. Abken. 2010. Do CARs need a driver's license? Adoptive cell therapy with chimeric antigen receptor-redirected T cells has caused serious adverse events. Hum. Gene Ther. 21: 1039-1042.
3. Rosenberg, S. A., J. C. Yang, R. M. Sherry, U. S. Kammula, M. S. Hughes, G. Q. Phan, D. E. Citrin, N. P. Restifo, P. F. Robbins, J. R. Wunderlich, et al. 2011. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin. Cancer Res. 17: 4550-4557.
4. Scott, A. M., J. D. Wolchok, and L. J. Old. 2012. Antibody therapy of cancer. Nat. Rev. Cancer 12: 278-287.
5. Hiraki, A., T. Kaneshige, K. Kiura, H. Ueoka, H. Yamane, M. Tanaka, and M. Harada. 1999. Loss of HLA haplotype in lung cancer cell lines: implications for immunosurveillance of altered HLA class I/II phenotypes in lung cancer. Clin. Cancer Res. 5: 933-936.
6. Gilham, D. E., R. Debets, M. Pule, R. E. Hawkins, and H. Abken. 2012. CART cells and solid tumors: tuning T cells to challenge an inveterate foe. Trends Mol. Med. 18: 377-384.
7. Davila, M. L., I. Rivière, X. Wang, S. Bartido, J. Park, K. Curran, S. S. Chung, J. Stefanski, O. Borquez-Ojeda, M. Olszewska, et al. 2014. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl. Med. 6: 224ra25. doi:10.1126/scitranslmed.3008226
8. Kochenderfer, J. N., M. E. Dudley, R. O. Carpenter, S. H. Kassim, J. J. Rose, W. G. Telford, F. T. Hakim, D. C. Halverson, D. H. Fowler, N. M. Hardy, et al. 2013. Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood 122: 4129-4139.
9. Grupp, S. A., M. Kalos, D. Barrett, R. Aplenc, D. L. Porter, S. R. Rheingold, D. T. Teachey, A. Chew, B. Hauck, J. F. Wright, et al. 2013. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 368: 1509-1518.
10. Brentjens, R. J., M. L. Davila, I. Rivière, J. Park, X. Wang, L. G. Cowell, S. Bartido, J. Stefanski, C. Taylor, M. Olszewska, et al. 2013. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci. Transl. Med. 5: 177ra38. doi: 10.1126/scitranslmed.3005930
11. Lamers, C. H. J., S. Sleijfer, A. G. Vulto, W. H. J. Kruit, M. Kliffen, R. Debets, J. W. Gratama, G. Stoter, and E. Oosterwijk. 2006. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J. Clin. Oncol. 24: e20-e22.
12. Kershaw, M. H., J. A. Westwood, L. L. Parker, G. Wang, Z. Eshhar, S. A. Mavroukakis, D. E. White, J. R. Wunderlich, S. Canevari, L. Rogers-Freezer, et al. 2006. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin. Cancer Res. 12: 6106-6115.
13. Park, J. R., D. L. Digiusto, M. Slovak, C. Wright, A. Naranjo, J. Wagner, H. B. Meechoovet, C. Bautista, W.-C. Chang, J. R. Ostberg, and M. C. Jensen. 2007. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol. Ther. 15: 825-833.
14. Toyokuni, S., K. Okamoto, J. Yodoi, and H. Hiai. 1995. Persistent oxidative stress in cancer. FEBS Lett. 358: 1-3.
15. Brown, N. S., and R. Bicknell. 2001. Hypoxia and oxidative stress in breast cancer. Oxidative stress: its effects on the growth, metastatic potential and response to therapy of breast cancer. Breast Cancer Res. 3: 323-327.
16. Poschke, I., and R. Kiessling. 2012. On the armament and appearances of human myeloid-derived suppressor cells. Clin. Immunol. 144: 250-268.
17. Corzo, C. A., M. J. Cotter, P. Cheng, F. Cheng, S. Kusmartsev, E. Sotomayor, T. Padhya, T. V. McCaffrey, J. C. McCaffrey, and D. I. Gabrilovich. 2009. Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells. J. Immunol. 182: 5693-5701.
18. Schmielau, J., and O. J. Finn. 2001. Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. Cancer Res. 61: 4756-4760.
19. Kiessling, R., Y. Mao, and Y. Pico de Coaña. 2014. Myeloid suppressors decrease melanoma survival by abating tumor-fighting T cells. Clin. Cancer Res. 20: 1401-1403.
20. +) T cells by oxidative stress associated with block of NF-kB activation. J. Immunol. 167: 2595-2601.
21. 2) T cells by hydrogen peroxide-induced oxidative stress. J. Immunol. 174: 6080-6087.
22. Kono, K., F. Salazar-Onfray, M. Petersson, J. Hansson, G. Masucci, K. Wasserman, T. Nakazawa, P. Anderson, and R. Kiessling. 1996. Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing z molecules and inhibits tumor-specific T cell-and natural killer cell-mediated cytotoxicity. Eur. J. Immunol. 26: 1308-1313.
23. Nakagomi, H., M. Petersson, I. Magnusson, C. Juhlin, M. Matsuda, H. Mellstedt, J. L. Taupin, E. Vivier, P. Anderson, and R. Kiessling. 1993. Decreased expression of the signal-transducing z chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer Res. 53: 5610-5612.
24. Mizoguchi, H., J. J. O'Shea, D. L. Longo, C. M. Loeffler, D. W. McVicar, and A. C. Ochoa. 1992. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 258: 1795-1798.
25. Meyer, C., A. Sevko, M. Ramacher, A. V. Bazhin, C. S. Falk, W. Osen, I. Borrello, M. Kato, D. Schadendorf, M. Baniyash, and V. Umansky. 2011. Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model. Proc. Natl. Acad. Sci. USA 108: 17111-17116.
26. Ando, T., K. Mimura, C. C. Johansson, M. G. Hanson, D. Mougiakakos, C. Larsson, T. Martins da Palma, D. Sakurai, H. Norell, M. Li, et al. 2008. Transduction with the antioxidant enzyme catalase protects human T cells against oxidative stress. J. Immunol. 181: 8382-8390.
27. Hombach, A., D. Sent, C. Schneider, C. Heuser, D. Koch, C. Pohl, B. Seliger, and H. Abken. 2001. T-cell activation by recombinant receptors: CD28 co-stimulation is required for interleukin 2 secretion and receptor-mediated T-cell proliferation but does not affect receptor-mediated target cell lysis. Cancer Res. 61: 1976-1982.
28. Chmielewski, M., A. A. Hombach, and H. Abken. 2011. CD28 cosignalling does not affect the activation threshold in a chimeric antigen receptor-redirected T-cell attack. Gene Ther. 18: 62-72.
29. Imada, I., E. F. Sato, M. Miyamoto, Y. Ichimori, Y. Minamiyama, R. Konaka, and M. Inoue. 1999. Analysis of reactive oxygen species generated by neutro-phils using a chemiluminescence probe L-012. Anal. Biochem. 271: 53-58.
30. Devadas, S., L. Zaritskaya, S. G. Rhee, L. Oberley, and M. S. Williams. 2002. Discrete generation of superoxide and hydrogen peroxide by T cell receptor stimulation: selective regulation of mitogen-activated protein kinase activation and fas ligand expression. J. Exp. Med. 195: 59-70.
31. Porter, D. L., B. L. Levine, M. Kalos, A. Bagg, and C. H. June. 2011. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365: 725-733.
32. Kono, K., M. E. Ressing, R. M. Brandt, C. J. Melief, R. K. Potkul, B. Andersson, M. Petersson, W. M. Kast, and R. Kiessling. 1996. Decreased expression of signal-transducing z chain in peripheral T cells and natural killer cells in patients with cervical cancer. Clin. Cancer Res. 2: 1825-1828.
33. dim subset. J. Immunol. 179: 4513-4519.
34. Schreiber, R. D., L. J. Old, and M. J. Smyth. 2011. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331: 1565-1570.
35. Mao, Y., I. Poschke, and R. Kiessling. 2014. Tumour-induced immune suppression: role of inflammatory mediators released by myelomonocytic cells. J. Intern. Med. 276: 154-170.
36. Hombach, A., C. Schlimper, E. Sievers, S. Frank, H. H. Schild, T. Sauerbruch, I. G. Schmidt-Wolf, and H. Abken. 2006. A recombinant anti-carcinoembryonic antigen immunoreceptor with combined CD3z-CD28 signalling targets T cells from colorectal cancer patients against their tumour cells. Gut 55: 1156-1164.
37. Moasser, M. M. 2007. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 26: 6469-6487.
38. Beauchemin, N., and A. Arabzadeh. 2013. Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) in cancer progression and metastasis. Cancer Metastasis Rev. 32: 643-671.
39. Kondo, S., S. Toyokuni, Y. Iwasa, T. Tanaka, H. Onodera, H. Hiai, and M. Imamura. 1999. Persistent oxidative stress in human colorectal carcinoma, but not in adenoma. Free Radic. Biol. Med. 27: 401-410.
40. Kang, K. A., K. C. Kim, S. C. Bae, and J. W. Hyun. 2013. Oxidative stress induces proliferation of colorectal cancer cells by inhibiting RUNX3 and activating the Akt signaling pathway. Int. J. Oncol. 43: 1511-1516.
41. Soliman, A. S., S. V. Vulimiri, H. E. Kleiner, J. Shen, S. Eissa, M. Morad, H. Taha, F. Lukmanji, D. Li, D. A. Johnston, et al. 2004. High levels of oxidative DNA damage in lymphocyte DNA of premenopausal breast cancer patients from Egypt. Int. J. Environ. Health Res. 14: 121-134.
42. Pagès, F., A. Berger, M. Camus, F. Sanchez-Cabo, A. Costes, R. Molidor, B. Mlecnik, A. Kirilovsky, M. Nilsson, D. Damotte, et al. 2005. Effector memory T cells, early metastasis, and survival in colorectal cancer. N. Engl. J. Med. 353: 2654-2666.
43. Lockhart, D. C., A. K. Chan, S. Mak, H.-G. Joo, H. A. Daust, A. Carritte, C. C. Douville, P. S. Goedegebuure, and T. J. Eberlein. 2001. Loss of T-cell receptor-CD3z and T-cell function in tumor-infiltrating lymphocytes but not in tumor-associated lymphocytes in ovarian carcinoma. Surgery 129: 749-756.
44. Ishigami, S., S. Natsugoe, K. Tokuda, A. Nakajo, H. Higashi, H. Iwashige, K. Aridome, S. Hokita, and T. Aikou. 2002. CD3-zetachain expression of intratumoral lymphocytes is closely related to survival in gastric carcinoma patients. Cancer 94: 1437-1442.
45. Seaman, W. E., T. D. Gindhart, M. A. Blackman, B. Dalal, N. Talal, and Z. Werb. 1982. Suppression of natural killing in vitro by monocytes and polymorpho-nuclear leukocytes: requirement for reactive metabolites of oxygen. J. Clin. Invest. 69: 876-888.
46. Zhang, L., Z. Yu, P. Muranski, D. C. Palmer, N. P. Restifo, S. A. Rosenberg, and R. A. Morgan. 2013. Inhibition of TGF-b signaling in genetically engineered tumor antigen-reactive T cells significantly enhances tumor treatment efficacy. Gene Ther. 20: 575-580.